Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.

The acquisition moves Switchboard beyond specialty-care navigation into direct care delivery by integrating Livara’s virtual-first, value-based MSK model, alongside more than $5 million in new financing.

The transaction combines Valerio’s targeted delivery technologies with Etherna’s mRNA, lipid nanoparticle and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.

The acquisition adds clinical research, biomarker, laboratory, market access and commercialisation capabilities to McKesson’s Oncology & Multispecialty business, extending its services across the drug-development pathway.

The combination will create a Nasdaq-listed Ambros Therapeutics focused on neridronate, backed by a concurrent $150 million private placement expected to fund the programme through Phase III results and a planned FDA submission.

The acquisition makes Yapan Bio a Piramal Pharma subsidiary, strengthening the company's integrated biologics development and manufacturing offering for vaccines, biologics and antibody-drug conjugates.

The acquisition gives BioMarin access to ALE1, a potential first oral treatment for hypophosphatasia, while expanding its rare disease pipeline with a clinical-stage skeletal disease programme.

The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.

The completed acquisition adds MediSix’s PEBL T-cell engineering technology, clinical pipeline and Singapore-based R&D team to IASO Bio’s existing cell therapy development, manufacturing and commercial capabilities.

The transaction creates a Nasdaq-listed fibrosis-focused company led by Redx’s management, with financing expected to fund the Phase II development of lead Crohn’s disease candidate RXC008 and provide cash runway into 2029.

The acquisition would add a BLA-stage, one-time AAV gene therapy to PTC’s rare disease portfolio, with a rolling US submission expected to complete in the fourth quarter of 2026.

The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan.

The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients.

The acquisition adds SimoTech’s automation engineering and digital manufacturing expertise to Project Farma’s existing life sciences manufacturing services, creating a broader offering spanning facility strategy through GMP operations.

The acquisition would add a clinical-stage KCNT1 inhibitor for a rare genetic epilepsy with no FDA-approved treatments, while Actio’s remaining programmes will be transferred into a separate privately held company.

The completed transaction combines Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial infrastructure, giving the company end-to-end control across biosimilar development, production and commercialisation.

The proposed acquisition gives Wise Equity control of a specialist oral solid-dose manufacturer with established capabilities in effervescent, soluble, orally disintegrating and sublingual formulations.

The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.

The stock-for-stock acquisition adds a clinical-stage neuroplastogenic pain programme to Ensysce’s pipeline, with concurrent financing expected to fund CY200 through Phase II proof-of-concept data and towards registrational development.

The proposed acquisition would add Xycota’s preclinical CNS pipeline and exosome-based delivery platform to NexTel Medical, including lead programme XYCO-01 for frontotemporal dementia.